Background
Methods
Patient recruitment and follow-up
DNA extraction and genotyping
Statistical analysis
Results
Patient characteristics
Variable | Patients (%) | MST(mon) | Log-rank P value | HR (95%CI) |
---|---|---|---|---|
Age (years) | ||||
≤50 | 105(40.9) | 14.93 | 0.493 | 1.00 |
>50 | 152(59.1) | 12.47 | 1.10(0.84-1.45) | |
Tumor stage | ||||
I | 44(17.1) | 45.80 | 1.00 | |
II | 34(13.2) | 18.57 | < 0.001 | 2.48(1.36-4.53) |
III | 149(58.0) | 11.07 | 3.46(2.14-5.61) | |
IV | 30(11.7) | 9.07 | 4.66(2.59-8.37) | |
Surgical operation | ||||
No | 53(20.6) | 6.20 | 0.005 | 1.00 |
Yes | 204(79.4) | 15.50 | 0.61(0.44-0.86) | |
Chemotherapy or radiotherapy | ||||
No | 31(12.1) | 9.00 | 0.803 | 1.00 |
Yes | 226(87.9) | 13.30 | 0.94(0.59-1.51) |
Genotype frequencies of genetic polymorphisms
Genotype | Patients(%) | MST(mon) | Log-rank P | HR(95%CI) | Adjusted HR(95%CI)A
|
---|---|---|---|---|---|
ERCC2 Lys751Gln | |||||
AA | 194(75.5) | 14.50 | 1.00 | 1.00 | |
AC | 59(23.0) | 10.40 | 0.10 | 1.40(1.01-1.94) | 1.32(0.95-1.84) |
CC | 4(1.5) | 12.27 | 0.73(0.23-2.28) | 0.79(0.25-2.48) | |
AC/CCB
| 63(24.5) | 10.97 | 0.08 | 1.33(0.97-1.82) | 1.27(0.92-1.75) |
ERCC2 Asp312Asn | |||||
GG | 229(89.1) | 13.23 | 1.00 | 1.00 | |
GA | 27(10.5) | 12.40 | 0.05 | 0.95(0.60-1.49) | 0.95(0.60-1.49) |
AA | 1(0.4) | 4.40 | 8.25(1.12-60.60) | 8.55(1.14-64.25) | |
GA/AAC
| 28(10.9) | 9.83 | 0.96 | 0.99(0.63-1.54) | 0.99(0.63-1.54) |
ERCC1 Asn118Asn | |||||
CC | 140(54.5) | 17.23 | 1.00 | 1.00 | |
CT | 94(36.6) | 11.07 | < 0.001 | 1.58(1.18-2.12) | 1.48(1.10-1.99) |
TT | 23(8.9) | 6.20 | 2.82(1.72-4.62) | 2.67(1.62-4.40) | |
XRCC1 Arg399Gln | |||||
GG | 117(45.5) | 19.10 | 1.00 | 1.00 | |
GA | 102(39.7) | 10.40 | < 0.001 | 1.41(1.05-1.91) | 1.28(0.95-1.74) |
AA | 38(14.8) | 9.23 | 2.33(1.56-3.47) | 2.68(1.79-4.02) |
Genetic polymorphisms and survival of patients
Stage | Combined genotype | Patients(%) | MST(mon) | Log-rank P | HR(95%CI)a
|
---|---|---|---|---|---|
all | 0 variant | 67(26.1) | 25.10 | 1.00 | |
1 variant allele | 100(38.9) | 13.07 | 1.52(1.04-2.22) | ||
2 variant alleles | 58(22.6) | 9.27 | < 0.001 | 2.33(1.54-3.50) | |
3 variant alleles | 26(10.1) | 6.30 | 2.98(1.76-5.04) | ||
4 variant alleles | 6(2.3) | 3.87 | 9.24(3.50-24.44) | ||
I and II | 0 variant | 26(33.3) | 45.80 | 1.00 | |
1 variant allele | 30(38.5) | 22.27 | 1.98(0.86-4.58) | ||
2 variant alleles | 14(17.9) | 11.60 | 0.145 | 2.81(1.10-7.13) | |
3 variant alleles | 6(7.7) | --b
| 1.41(0.26-6.75) | ||
4 variant alleles | 2 (2.6) | 17.27 | 9.05(1.04-78.76) | ||
III and IV | 0 variant | 41(22.9) | 19.10 | 1.00 | |
1 variant allele | 70(39.1) | 11.17 | 1.54(0.98-2.39) | ||
2 variant alleles | 44(24.6) | 8.93 | < 0.001 | 2.29(1.44-3.66) | |
3 variant alleles | 20(11.2) | 5.83 | 3.69(2.06-6.62) | ||
4 variant alleles | 4(2.2) | 3.63 | 18.50(5.68-60.23) |
ERCC1CC |
ERCC1 CT/TT | |||
---|---|---|---|---|
XRCC1
| MST | HR(95%CI)A
| MST | HR(95%CI)A
|
GG | 25.10 | 1.00 | 13.30 | 1.79(1.16-2.76) |
GA/AA | 12.47 | 1.64(1.11-2.44) | 8.60 | 2.44(1.63-3.65) |
Variable | β | SEM | HR | 95%CI | P value |
---|---|---|---|---|---|
stage (III+ IV vs. I+II) | 0.661 | 0.102 | 1.94 | 1.59-2.36 | < 0.001 |
chemotherapy or radiotherapy | -1.095 | 0.307 | 0.34 | 0.18-0.61 | < 0.001 |
ERCC1 118 (CT/TT vs. CC) | 0.473 | 0.142 | 1.60 | 1.22-2.12 | 0.001 |
XRCC1 399 (GA/AA vs. GG) | 0.405 | 0.143 | 1.50 | 1.13-1.98 | 0.005 |